Clinical Trials Logo

Melanoma and Brain Metastases clinical trials

View clinical trials related to Melanoma and Brain Metastases.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02039947 Completed - Clinical trials for Melanoma and Brain Metastases

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Start date: February 21, 2014
Phase: Phase 2
Study type: Interventional

This is a multi-cohort, open label, Phase II study with Dabrafenib (GSK2118436) and Trametinib (GSK1120212) combination therapy in subject with BRAF mutation-positive melanoma that has metastasized to the brain. This study will evaluate the safety and efficacy of 4 cohorts. Cohorts will consist of; V600 E, D, K, R mutations, metastases to the brain, symptomatic and asymptomatic, with or without prior local (brain) therapy, with or without prior local (brain) therapy, and range of ECOG scores from 0-2.

NCT ID: NCT01266967 Completed - Clinical trials for Melanoma and Brain Metastases

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain

Break MB
Start date: February 2011
Phase: Phase 2
Study type: Interventional

This study is designed to assess the efficacy, pharmacokinetics, safety, and tolerability of an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with BRAF V600E or V600K mutation-positive metastatic melanoma to the brain. Subjects in Cohort A will not have received any local brain therapy, and subjects in Cohort B will have received prior local therapy for brain metastases. Subjects will continue on treatment until disease progression, death, or unacceptable adverse event.